Resistance to anti-epidermal growth factor receptor (EGFR) therapy and the efficacy of anti-HER2 treatment suggest that HER2 amplification is an actionable alteration in CRC [8,9,10]. The gene discussed is EGFR; the disease is colorectal carcinoma.